Korea FilingsFull brief — $39

PharmGen Science, Inc.

(주)팜젠사이언스 · KOSPI: 004720 · Pharmaceuticals and medicinal chemicals

Key facts

Korean name
(주)팜젠사이언스
Market / ticker
KOSPI · 004720
Industry
Pharmaceuticals and medicinal chemicals
Established
1966-08-22
Fiscal year ends
December
Website
www.pharmgenscience.com
DART corp code
00135050
Latest revenue
₩173.1B (FY2025)

Items worth checking

medium
Filing on change of largest shareholder or control — filed 2025-12-12.
low
Conversion / warrant / exchange rights exercised — shares outstanding change — filed on 3 separate dates in the last 12 months, latest 2026-05-12.
low
Filing on a change in the CEO line-up — filed 2026-03-31.

Financial summary

KRWFY2023FY2024FY2025
Revenue₩166.8B₩171.3B₩173.1B
Operating income₩9.1B₩10.6B₩6.0B
Net income₩6.1B₩2.8B−₩116.6B
Total assets₩342.0B₩363.5B₩195.4B
Total liabilities₩109.0B₩114.0B₩49.1B
Total equity₩233.0B₩249.4B₩146.3B
Share capital₩9.0B₩9.1B₩11.0B

Separate statements · FY2025 operating margin 3.5% · liabilities to equity 34% · Annual report FY2025 (Korean original)

Auditor opinions

PeriodAuditorOpinion
Term 60 (current)삼정회계법인Unqualified
Term 59 (prior)태일회계법인 (구, 회계법인 세일원)Unqualified
Term 59 (prior)태일회계법인 (구, 회계법인 세일원)Unqualified
Term 58 (two years prior)회계법인 세일원Unqualified

Largest shareholder history

DateLargest shareholder (Korean)StakeCause (Korean)
2020년 06월 03일에이치디투자조합주식양수도계약
2025년 12월 11일한의상33CB 전환청구권 행사

Recent filings

DateFilingOriginal
2026-08-14Half-year report (2026.06)DART
2026-06-01Corporate governance reportDART
2026-05-15Quarterly report (2026.03)DART
2026-05-15Amended: Annual report (2025.12)DART
2026-05-12Officer / major shareholder ownership reportDART
2026-05-12Large shareholding (5%+) reportDART
2026-05-12Change in shareholdings of largest shareholderDART
2026-05-12Conversion / warrant / exchange rights exercisedDART
2026-03-31Independent director appointment / dismissal / resignationDART
2026-03-31Change of CEO (notice)DART
2026-03-31Annual general meeting resultsDART
2026-03-23Amended: Proxy solicitation reference documentDART
2026-03-23Amended: Notice of shareholders meetingDART
2026-03-23Annual report (2025.12)DART
2026-03-23Audit report submittedDART
2026-03-12Proxy solicitation reference documentDART
2026-03-12Notice of shareholders meetingDART
2026-03-12Resolution to convene shareholders meetingDART
2026-03-11Adjustment of conversion / exercise / exchange price (notice)DART
2026-02-09Revenue or profit structure changed materiallyDART

Showing the 20 most recent of 31 filings. The full brief lists all of them.

Full brief on PharmGen Science, Inc. — $39 Get the full brief

For business customers. EU companies: enter your VAT number at checkout and no VAT is charged (reverse charge).

Other Korean companies in Pharmaceuticals and medicinal chemicals

Data generated 2026-09-16 from OpenDART.

This page summarizes public filings from DART, the official electronic disclosure system of Korea. It is not investment, credit or legal advice. Figures are shown in the currency the company reports in. Titles and labels are machine-translated and may contain errors — always check the linked original filing. Source: OpenDART, Financial Supervisory Service, Korea.